Prediction of Overall Survival in Gastric Cancer by a Six-Gene Cox Proportional Hazards Model

  • Zihan Fang International School of Beijing
DOI: https://doi.org/10.18686/aem.v11i3.273
Keywords: Prognostic Genes, Gastric Cancer, Six-Gene Cox Proportional Hazards Model

Abstract

This study aims to investigate prognostic genes that are correlated with overall survival in gastric cancer. A list of 43 critical genes is first selected from literature review and is narrowed down using marginal analysis, false discovery rate (FDR). This study used the 16 differential genes selected by FDR to create a cox proportional hazards regression model. Using a stepwise approach, the cox model is refined. From the 16 genes, 6 genes significantly correlated with overall survival are chosen and kept in the cox model. A principal component regression model was also constructed based on the principal component analysis results. The concordance of the principal component regression model is then compared to the concordance of the cox proportional hazards regression model. The final 6 identified genes are NRP1, STK11, MCM2, MARCKS, CTS6, C5. Of the 6 genes, MARCKS, NRP1, STK11, MCM2 are in line with previous research. CTS6 and C5, although studied in other cancers, are comparatively novel in the field of gastric cancer.

References

[1] Arnold M et al. “Global Burden of 5 Major Types of Gastrointestinal Cancer.” Gastroenterology vol. 159,1 (2020): 335-349.e15.

[2] Bray F et al. “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.” CA: a cancer journal for clinicians vol. 68,6 (2018): 394-424.

[3] Busuttil RA, et al. “SFRP4 Drives Invasion in Gastric Cancer and Is an Early Predictor of Recurrence.” Gastric Cancer, vol. 24, no. 3, 2020, pp. 589–601.

[4] Cai L, et al. “The Better Survival of MSI Subtype Is Associated with the Oxidative Stress Related Pathways in Gastric Cancer.” Frontiers in Oncology, vol. 10, 2020.

[5] Champeris TS et al. “Licensing of DNA replication, cancer, pluripotency and differentiation: an interlinked world?.” Seminars in cell & developmental biology vol. 30 (2014): 174-80.

[6] Chen DH, et al. “SPOCK1 Promotes the Invasion and Metastasis of Gastric Cancer through Slug-Induced Epithelial-Mesenchymal Transition.” Journal of Cellular and Molecular Medicine, 2017.

[7] Cheong JH et al.” Development and validation of a prognostic and predictive 32-gene signature for gastric cancer”. Nature communications, 13, 774. 2022.

[8] Dai J et al. “Whole Genome Messenger RNA Profiling Identifies a Novel Signature to Predict Gastric Cancer Survival.” Clinical and translational gastroenterology vol. 10,1 (2019): e00004.

[9] DeMartino JA, et al. “The amino terminus of the human C5a receptor is required for high affinity C5a binding and for receptor activation by C5a but not C5a analogs.” The Journal of biological chemistry vol. 269,20 (1994): 14446-50.

[10] Eftang L, et al. “Up-regulation of CLDN1 in gastric cancer is correlated with reduced survival”. BMC Cancer 13, 586. 2013.

[11] Ferlay J, et al. “Cancer statistics for the year 2020: An overview.” International journal of cancer, 10.1002/ijc.33588. 5 Apr. 2021.

[12] Fragkos M, et al. “DNA replication origin activation in space and time.” Nature reviews. Molecular cell biology vol. 16,6 (2015): 360-74.

[13] Gu Y, et al. “Contactin 1: An Important and Emerging Oncogenic Protein Promoting Cancer Progression and Metastasis.” Genes, vol. 11, no. 8, 2020, p. 874.

[14] Huang HP, et al. “High expression of COL10A1 is associated with poor prognosis in colorectal cancer.” OncoTargets and therapy vol. 11 1571-1581. 20 Mar. 2018.

[15] Huang K, et al. “Identification of three predictors of gastric cancer progression and prognosis.” FEBS open bio vol. 10,9 (2020): 1891-1899.

[16] Huang YX, et al. “Identification of Novel Susceptible Genes of Gastric Cancer Based on Integrated Omics Data.” Frontiers in cell and developmental biology vol. 9 712020. 20 Jul. 2021.

[17] Ilic M, and Irena I. “Epidemiology of stomach cancer.” World journal of gastroenterology vol. 28,12 (2022): 1187-1203.

[18] Jin XF, et al. “P3H4 Overexpression Serves as a Prognostic Factor in Lung Adenocarcinoma.” Computational and Mathematical Methods in Medicine, vol. 2021, 2021, pp. 1–9.

[19] Jung H, et al. “The expression of claudin-1, claudin-2, claudin-3, and claudin-4 in gastric cancer tissue.” The Journal of surgical research vol. 167,2 (2011): e185-91.

[20] Junnila S, et al. “Gene Expression Analysis Identifies over-Expression ofcxcl1,Sparc,spp1, andsulf1in Gastric Cancer.” Genes, Chromosomes and Cancer, vol. 49, no. 1, 2010, pp. 28–39.

[21] Kim JM, et al. “Identification of Gastric Cancer–Related Genes Using a cDNA Microarray Containing Novel Expressed Sequence Tags Expressed in Gastric Cancer Cells.” Clinical Cancer research Vol. 11,2, 473–482. 15 Jan. 2005.

[22] Kyrlagkitsis I, and Karamanolis DG. “Genes and gastric cancer.” Hepato-gastroenterology vol. 51,55 (2004): 320-7.

[23] Li Q, et al. “Correlation of Cystatin E/M with Clinicopathological Features and Prognosis in Triple-Negative Breast Cancer.” Annals of clinical and laboratory science vol. 48,1 (2018): 40-44.

[24] Li Y, et al. “A Methylation‐Based Mrna Signature Predicts Survival in Patients with Gastric Cancer.” Cancer Cell International, vol. 20, no. 1, 2020.

[25] Li Z, and Xu XZ. “Post-Translational Modifications of the Mini-Chromosome Maintenance Proteins in DNA Replication.” Genes  vol. 10,5 331. 30 Apr. 2019.

[26] Liang S et al. “Identification of Skt11-regulated genes in chondrocytes by integrated bioinformatics analysis.” Gene vol. 677 (2018): 340-348.

[27] Liu J, et al. “Identification of Critical Genes in Gastric Cancer to Predict Prognosis Using Bioinformatics Analysis Methods.” Annals of Translational Medicine, vol. 8, no. 14, 2020, pp. 884–884.

[28] Liu X, et al. “Cancer-Associated Fibroblast Infiltration in Gastric Cancer: The Discrepancy in Subtypes Pathways and Immunosuppression.” Journal of Translational Medicine, vol. 19, no. 1, 2021.

[29] Liu ZP, et al. “Prediction and prognostic significance of ALOX12B and PACSIN1 expression in gastric cancer by genome-wide RNA expression and methylation analysis.” Journal of gastrointestinal oncology vol. 12,5 (2021): 2082-2092.

[30] Lu Y, et al. “Diagnostic, Therapeutic, and Prognostic Value of the Thrombospondin Family in Gastric Cancer.” Frontiers in Molecular Biosciences, vol. 8, 2021.

[31] Ma H, et al. “Identifying of Biomarkers Associated with Gastric Cancer Based on 11 Topological Analysis Methods of CytoHubba.” Scientific Reports, vol. 11, no. 1, 2021.

[32] Machlowska J, et al. “Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies.” International journal of molecular sciences vol. 21,11 4012. 4 Jun. 2020.

[33] Machlowska J, et al. “High-Throughput Sequencing of Gastric Cancer Patients: Unravelling Genetic Predispositions towards an Early-Onset Subtype.” Cancers, vol. 12, no. 7, 2020, p. 1981.

[34] Marimuthu A, et al. “Gene Expression Profiling of Gastric Cancer.” Journal of proteomics & bioinformatics vol. 4,4 (2011): 74-82.

[35] Meng Q, et al. “DNA Methylation Regulator-Mediated Modification Patterns and Tumor Microenvironment Characterization in Gastric Cancer.” Molecular Therapy - Nucleic Acids, vol. 24, 2021, pp. 695–710.

[36] Nitta H, et al. “Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness.” Oncology reports vol. 32,4 (2014): 1715-9.

[37] Niu XJ, et al. “Identification of Potential Diagnostic and Prognostic Biomarkers for Gastric Cancer Based on Bioinformatic Analysis.” Frontiers in genetics vol. 13 862105. 16 Mar. 2022.

[38] Quan RL, et al. “Prognostic Value of Upregulation of Myristoylated Alanine-Rich C-Kinase Substrate in Gastric Cancer.” Medical science monitor: international medical journal of experimental and clinical research vol. 25 279-287. 9 Jan. 2019.

[39] Shim HJ, et al. “BRCA1 And XRCC1 Polymorphisms Associated with Survival in Advanced Gastric Cancer Treated with Taxane and Cisplatin.” Cancer Science, vol. 101, no. 5, 2010, pp. 1247–1254.

[40] Slavin T, et al. “Genetics of gastric cancer: what do we know about the genetic risks?.” Translational gastroenterology and hepatology vol. 4 55. 29 Jul. 2019.

[41] “Stomach (Gastric) Cancer Key Statistics.” American Cancer Society, [Internet], Available from: https://www.cancer.org/cancer/ stomach-cancer/about/key-statistics.html.

[42] Sun LP, et al. Ai zheng = Aizheng = Chinese journal of cancer vol. 23,1 (2004): 36-9.

[43] Sun MY, et al. “Prognostic Implications of Novel Gene Signatures in Gastric Cancer Microenvironment.” Medical science monitor : international medical journal of experimental and clinical research vol. 26 e924604. 2 Aug. 2020.

[44] Szász AM, et al. “Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients.” Oncotarget vol. 7,31 (2016): 49322-49333.

[45] Vetrivel P, et al. “Investigation on the Cellular Mechanism of Prunetin Evidenced through next Generation Sequencing and Bioinformatic Approaches against Gastric Cancer.” Scientific Reports, vol. 12, no. 1, 2022.

[46] Wang GH, et al. “Hypomethylated gene NRP1 is co-expressed with PDGFRB and associated with poor overall survival in gastric cancer patients.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 111 (2019): 1334-1341.

[47] Wang GG, et al. “The prediction of survival in Gastric Cancer based on a Robust 13-Gene Signature.” Journal of Cancer vol. 12,11 3344-3353. 12 Apr. 2021.

[48] Wang P, et al. “A novel gene expression-based prognostic scoring system to predict survival in gastric cancer.” Oncotarget  vol. 7,34 (2016): 55343-55351.

[49] Pan YL et al. “KCNE2, a down-regulated gene identified by in silico analysis, suppressed proliferation of gastric cancer cells.” Cancer letters vol. 246,1-2 (2007): 129-38.

[50] Yuan J, et al. “Multi-Omics Analysis of MCM2 as a Promising Biomarker in Pan-Cancer.” Frontiers in cell and developmental biology vol. 10 852135. 25 May. 2022.

[51] Zeng DQ, et al. “Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures.” Cancer Immunology Research, vol. 7, no. 5, 2019, pp. 737–750.

[52] Zeng Z, et al. “Genome‐Wide Identification of CPG Island Methylator Phenotype Related Gene Signature as a Novel Prognostic Biomarker of Gastric Cancer.” PeerJ, vol. 8, 2020.

[53] Zhang L, et al. “Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 93 (2017): 1136-1143.

[54] Zhang YW, et al. “Multi-Omics Data Analyses Construct TME and Identify the Immune-Related Prognosis Signatures in Human LUAD.” Molecular Therapy - Nucleic Acids, vol. 21, 2020, pp. 860–873.

[55] Zhen Yuxu et al. ”Gene expression profile towards the prediction of patient survival of gastric cancer, Biomedicine & Pharmacotherapy, Volume 64, Issue 2, 2010, Pages 133-139.

[56] Zhou LQ, et al. “Establishment of a prognostic model of four genes in gastric cancer based on multiple data sets.” Cancer medicine vol. 10,10 (2021): 3309-3322.

[57] Zhuo et al. “Elevated THBS2, COL1A2, and SPP1 Expression Levels as Predictors of Gastric Cancer Prognosis”. Cell Physiol Biochem vol 40, 1316-1324. 2016.
Published
2022-11-02
Issue
Vol 11 No 3 (2022)
Section
Original Research Article

Copyright (c) 2022 Zihan Fang

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.